Patients on Ozempic report ‘waking up blind’ in as little as a day after using fat jab
PATIENTS taking blockbuster diabetes and weight loss drugs are waking up with vision loss, researchers warn. Some reported ...
Pharmaceutical Technology4h
Eli Lilly pledges $630m on OliX’s Phase I RNA candidate for MASH
Eli Lilly is paying up to $630m for a Phase I MASH candidate from OliX Pharmaceuticals, diversifying its pipeline with an RNA ...
emjreviews.com5h
High Discontinuation Rates of GLP-1 RAs Among Patients Without Type 2 Diabetes
Study finds that a significant proportion of adults prescribed GLP-1 RAs for weight management discontinue treatment within a ...
Daily6h
Elective Peri-Operative Management of Patients on GLP-1, GIP Agonists & SGLT-2 Inhibitors: Multidisciplinary Consensus Released
UK: A recent consensus statement from leading UK medical organizations-including the Association of Anaesthetists,the ...
Hosted on MSN20h
Super Bowl ad for copycat weight loss drugs stokes pharma power debate
Controversy surrounded Hims & Hers’ commercial, called ‘Sick of the System’, in the lead up to America’s biggest sporting event.
Popular weight-loss drugs show promise in reducing kidney disease complications and mortality
A well-known class of drugs used to manage type 2 diabetes and control weight could offer hope for patients who also struggle ...
News2422h
Which of the breakthrough weight-loss medicines can you get in SA?
Ozempic and other glucagon-like peptide-1 (GLP-1) agonists are a transformative new class of medicines for the treatment of diabetes and obesity, while also delivering other health benefits, such as ...
Review links 3 potentially-blinding eye conditions to GLP-1 drugs like Ozempic
A new review reports that nine people taking semaglutide and tirzepatide — the active ingredient in GLP-1 medications — ...